Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Cencora, Inc. (Formerly Reported as AmerisourceBergen Corporation)

2. Address

Address1
412 1st Street SE, Suite 200
 Address2
​
City
WASHINGTON
 State
DC
 Zip Code
20003
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​Daniel Grainger
​2028874940
​daniel.grainger@amerisourcebergen.com
5. Senate ID#
​293756-12
7. Client Name Self Check if client is a state or local government or instrumentality
​Cencora, Inc. (Formerly Reported as AmerisourceBergen Corporation)
6. House ID#
​373870000
TYPE OF REPORT 8. Year
​2023
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​410,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Daniel Grainger
 Date
10/20/2023 4:45:55 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicare Part B Reimbursement. Average Sales Price (ASP) generally (in the context of deficit reduction). Medicare Part B Biosimilar Reimbursement. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Recognizing pharmacists as providers within Medicare for COVID-19 response. The Equitable Community Access to Pharmacist Services Act (H.R. 1770). Inflation Reduction Act. Supporting Medicare Providers Act (H.R.8800). Medicare Access & CHIP Reauthorization Act (MACRA). Pharmacy and Medically Underserved Areas Enhancement Act. Seniors Access to Critical Medicines Act (H.R. 5526). Protecting Patient Access to Cancer and Complex Therapies Act (S. 2764). Reimbursement policies impacting drug shortages.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Vivienne S.
Mitchell
​
​
Shelly
Mui-Lipnik
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Legislation to provide for coverage under Medicare program of pharmacist services. Pharmacy and Medically Underserved Area Enhancement Act. Medication therapy management. Legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. House and Senate Agriculture, FDA, and related agency Appropriations bills. House and Senate Labor/HHS appropriations bills. Prescription drug importation. Issues and policies related to generic drug shortages. Recognizing pharmacists as providers within Medicare for COVID-19 response. The Equitable Community Access to Pharmacist Services Act (H.R. 1770/S.2477) and permanent extension of PREP Act Declarations for pharmacist clinical services.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Vivienne S.
Mitchell
​
​
Shelly
Mui-Lipnik
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Advancing Emergency Preparedness through One Health Act. Strengthening Americas Strategic National Stockpile Act. Essential Medicines Strategic Stockpile Act. Ensuring essential medication supply for military and Department of Defense. National Defense Authorization Act. digital communication of prescribing information. Prescription Information Modernization Act. Implementation of Consolidated Appropriations Act. Drug Shortages. H.R. 501 - Block, Report and Suspend Suspicious Shipments Act. Pandemic and All Hazards Preparedness Reauthorization. Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S. 2510). SUPPORT Act Reauthorization. FY 2024 National Defense Authorization Act. Medical and Health Stockpile Accountability Act of 2023 (H.R.3577). Drug Origin Transparency Act of 2023 (H.R. 3810). E&C and Finance Request for Information (RFI) to Inform Policymaking on Drug Shortages. House E&C Drug Shortages Discussion Draft.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Vivienne S.
Mitchell
​
​
Shelly
Mui-Lipnik
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)